Of 738 patients with metastatic nonsquamous NSCLC who initiated first-line pembrolizumab-combination therapy on or after May 10, 2017, a total of 283 patients (38%) met the eligibility criteria for this analysis with tumors testing negative for EGFR and ALK genomic aberrations and ECOG PS of 0 or 1 (Fig. 1). This evidence concerns the gene EGFR and non-small cell lung carcinoma.